Cargando…

Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells

BACKGROUND: Tumor glycolysis is a critical event for tumor progression. Docetaxel is widely used as a first-line drug for chemotherapy and shown to have a survival advantage. However, the role of docetaxel in tumor glycolysis remained poorly understood. METHODS: The effect of Docetaxel in tumor glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Junming, He, Zhijun, Yuan, Yeqing, Xie, Jing, Zhou, Yu, Guo, Baochun, Guo, Jinan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762006/
https://www.ncbi.nlm.nih.gov/pubmed/36536346
http://dx.doi.org/10.1186/s12964-022-00950-z
_version_ 1784852782972403712
author Peng, Junming
He, Zhijun
Yuan, Yeqing
Xie, Jing
Zhou, Yu
Guo, Baochun
Guo, Jinan
author_facet Peng, Junming
He, Zhijun
Yuan, Yeqing
Xie, Jing
Zhou, Yu
Guo, Baochun
Guo, Jinan
author_sort Peng, Junming
collection PubMed
description BACKGROUND: Tumor glycolysis is a critical event for tumor progression. Docetaxel is widely used as a first-line drug for chemotherapy and shown to have a survival advantage. However, the role of docetaxel in tumor glycolysis remained poorly understood. METHODS: The effect of Docetaxel in tumor glycolysis and proliferation were performed by CCK-8, Western blotting, real-time PCR, glucose, and lactate detection and IHC. ChIP and luciferase assay were used to analyze the mechanism of Docetaxel on Smad3-mediated HIF-1α transactivity. RESULTS: In this study, we showed that docetaxel treatment led to a significant inhibition of cell proliferation in prostate cancer cells through PFKP-mediated glycolysis. Addition of lactate, a production of glycolysis, could reverse the inhibitory effect of docetaxel on cell proliferation. Further analysis has demonstrated that phosphorylation of Smad3 (Ser213) was drastically decreased in response to docetaxel stimulation, leading to reduce Smad3 nuclear translocation. Luciferase and Chromatin immunoprecipitation (ChIP) analysis revealed that docetaxel treatment inhibited the binding of Smad3 to the promoter of the HIF-1α gene, suppressing transcriptional activation of HIF-1α. Moreover, ectopic expression of Smad3 in prostate cancer cells could overcome the decreased HIF-1α expression and its target gene PFKP caused by docetaxel treatment. Most importantly, endogenous Smad3 regulated and interacted with HIF-1α, and this interaction was destroyed in response to docetaxel treatment. What’s more, both HIF-1α and PFKP expression were significantly reduced in prostate cancer received docetaxel treatment in vivo. CONCLUSION: These findings extended the essential role of docetaxel and revealed that docetaxel inhibited cell proliferation by targeting Smad3/HIF-1α signaling-mediated tumor Warburg in prostate cancer cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00950-z.
format Online
Article
Text
id pubmed-9762006
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97620062022-12-20 Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells Peng, Junming He, Zhijun Yuan, Yeqing Xie, Jing Zhou, Yu Guo, Baochun Guo, Jinan Cell Commun Signal Research BACKGROUND: Tumor glycolysis is a critical event for tumor progression. Docetaxel is widely used as a first-line drug for chemotherapy and shown to have a survival advantage. However, the role of docetaxel in tumor glycolysis remained poorly understood. METHODS: The effect of Docetaxel in tumor glycolysis and proliferation were performed by CCK-8, Western blotting, real-time PCR, glucose, and lactate detection and IHC. ChIP and luciferase assay were used to analyze the mechanism of Docetaxel on Smad3-mediated HIF-1α transactivity. RESULTS: In this study, we showed that docetaxel treatment led to a significant inhibition of cell proliferation in prostate cancer cells through PFKP-mediated glycolysis. Addition of lactate, a production of glycolysis, could reverse the inhibitory effect of docetaxel on cell proliferation. Further analysis has demonstrated that phosphorylation of Smad3 (Ser213) was drastically decreased in response to docetaxel stimulation, leading to reduce Smad3 nuclear translocation. Luciferase and Chromatin immunoprecipitation (ChIP) analysis revealed that docetaxel treatment inhibited the binding of Smad3 to the promoter of the HIF-1α gene, suppressing transcriptional activation of HIF-1α. Moreover, ectopic expression of Smad3 in prostate cancer cells could overcome the decreased HIF-1α expression and its target gene PFKP caused by docetaxel treatment. Most importantly, endogenous Smad3 regulated and interacted with HIF-1α, and this interaction was destroyed in response to docetaxel treatment. What’s more, both HIF-1α and PFKP expression were significantly reduced in prostate cancer received docetaxel treatment in vivo. CONCLUSION: These findings extended the essential role of docetaxel and revealed that docetaxel inhibited cell proliferation by targeting Smad3/HIF-1α signaling-mediated tumor Warburg in prostate cancer cells. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00950-z. BioMed Central 2022-12-19 /pmc/articles/PMC9762006/ /pubmed/36536346 http://dx.doi.org/10.1186/s12964-022-00950-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Peng, Junming
He, Zhijun
Yuan, Yeqing
Xie, Jing
Zhou, Yu
Guo, Baochun
Guo, Jinan
Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells
title Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells
title_full Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells
title_fullStr Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells
title_full_unstemmed Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells
title_short Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells
title_sort docetaxel suppressed cell proliferation through smad3/hif-1α-mediated glycolysis in prostate cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762006/
https://www.ncbi.nlm.nih.gov/pubmed/36536346
http://dx.doi.org/10.1186/s12964-022-00950-z
work_keys_str_mv AT pengjunming docetaxelsuppressedcellproliferationthroughsmad3hif1amediatedglycolysisinprostatecancercells
AT hezhijun docetaxelsuppressedcellproliferationthroughsmad3hif1amediatedglycolysisinprostatecancercells
AT yuanyeqing docetaxelsuppressedcellproliferationthroughsmad3hif1amediatedglycolysisinprostatecancercells
AT xiejing docetaxelsuppressedcellproliferationthroughsmad3hif1amediatedglycolysisinprostatecancercells
AT zhouyu docetaxelsuppressedcellproliferationthroughsmad3hif1amediatedglycolysisinprostatecancercells
AT guobaochun docetaxelsuppressedcellproliferationthroughsmad3hif1amediatedglycolysisinprostatecancercells
AT guojinan docetaxelsuppressedcellproliferationthroughsmad3hif1amediatedglycolysisinprostatecancercells